Roboearth – Lifestyle
Author:
MBX Biosciences, Inc.
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
May 7, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
April 23, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 26, 2026
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
March 12, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
March 10, 2026
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 9, 2026